Immuneering
Logotype for Immuneering Corporation

Immuneering (IMRX) investor relations material

Immuneering Study update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Immuneering Corporation
Study update summary12 Nov, 2026

Atebimetinib rationale and pipeline

  • Oral, once-daily third-generation MEK inhibitor designed for deep, transient pathway inhibition followed by a recovery window; intended to improve tolerability and preserve body mass.

  • Combination programs span chemotherapy, CLDN18.2-targeted agents, PRMT5 inhibitors, G12D/G12V inhibitors and immunotherapy.

  • Atebimetinib plus cemiplimab study expected to dose its first patient by year-end; an NSCLC anti-PD-1 program is also planned to start before year-end.

Pancreatic cancer

  • Interim Phase 2 analysis of 55 patients treated at 320 mg once daily showed median overall survival of 17.3 months; 84% of evaluable patients maintained or gained weight at 3 months. H1 2027 update planned.

  • MAPKeeper 301, a global Phase 3 trial of atebimetinib plus gemcitabine/nab-paclitaxel in first-line metastatic disease, began dosing and was enrolling ahead of schedule; topline results expected mid-2028.

  • Two Astellas-sponsored studies will test investigational CLDN18.2 combinations: one adds a CLDN18.2 candidate to atebimetinib plus mGnP in first-line disease; the other tests a chemotherapy-free regimen in previously treated disease.

  • Astellas will sponsor and conduct the studies, and atebimetinib supply will be provided; each party retains development and commercialization rights to its respective investigational medicines. The collaboration is the fourth pharma partnership.

Anaplastic thyroid cancer

  • Planned Phase 2 study evaluates second-line atebimetinib plus carboplatin and pemetrexed in MAPK-altered ATC after first-line standard treatment; cohorts address BRAF V600E and other eligible disease.

  • Design includes a six-patient safety run-in, followed by cohorts of ~29 patients each; atebimetinib dose is 320 mg. Primary endpoint is objective response rate.

  • Secondary endpoints include duration of response, disease control rate, progression-free survival, safety and overall survival; study was designed with investigators from four leading ATC centers and is considered potentially registrational.

  • IND submission planned by year-end; pending regulatory clearance, first dosing targeted for mid-2027, with top-line results potentially 12–18 months after dosing begins.

  • MAP kinase pathway drivers occur in most ATC cases, including ~40% with BRAF mutations and 33% with other mutations; second-line options remain limited.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Immuneering earnings date

Logotype for Immuneering Corporation
Q4 20268 Mar, 2027
Immuneering
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Immuneering earnings date

Logotype for Immuneering Corporation
Q4 20268 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Immuneering Corporation is a clinical-stage oncology company focused on developing novel therapeutics for cancer patients. The company leverages bioinformatics and computational biology to design drugs that cyclically disrupt core oncogenic signaling pathways, such as the MAPK pathway, with the aim of reducing tumor growth while minimizing toxicity. Immuneering’s pipeline includes its lead product candidate, IMM-1-104, a dual-MEK inhibitor in clinical trials targeting cancers caused by mutations in RAS and/or RAF. Another notable candidate is IMM-6-415, also targeting solid tumors. The company emphasizes a disease-agnostic approach, aiming to address cancers with high unmet medical needs through insights derived from its translational bioinformatics platform. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.